NEW YORK, June 12, 2017 /PRNewswire/ --
DailyStockTracker.com reviews for today Ironwood Pharmaceuticals
Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Supernus
Pharmaceuticals Inc. (NASDAQ: SUPN), and Pacira Pharmaceuticals
Inc. (NASDAQ: PCRX). According to Research and Markets' report,
titled "Analyzing the Generic Drugs Sector of the US
Pharmaceutical Industry 2017," the US is the biggest Generic
Drugs market in the world. In fact, nearly 80% of the prescriptions
written in the US are for generic drugs. These free stocks reports
are currently available on DailyStockTracker.com. Simply sign up
for your complimentary member access at:
http://dailystocktracker.com/register/
Ironwood Pharma
Cambridge, Massachusetts
headquartered Ironwood Pharmaceuticals Inc.'s shares declined
0.94%, finishing last Friday's session at $17.83. A total volume of 910,460 shares was
traded. Over the last month and the previous three months, the
stock has advanced 1.89% and 2.65%, respectively. Furthermore, the
Company's shares have gained 16.61% since the start of this year.
The stock is trading above its 50-day and 200-day moving averages
by 4.68% and 12.61%, respectively. Additionally, shares of Ironwood
Pharma, which engages in the research, development, and
commercialization of human therapeutic products, have a Relative
Strength Index (RSI) of 52.28.
On June 08th, 2017,
Ironwood Pharma announced that it will present a corporate update
at the Goldman Sachs 38th Annual Global Healthcare
Conference on June 15th,
2017, at 1:00 p.m. ET at the Terranea
Resort in Rancho Palos Verdes,
California. A live webcast of the presentation will be
accessible under the Investors section of the Company's
website. Your complete research report on IRWD can be
retrieved for free at:
http://dailystocktracker.com/registration/?symbol=IRWD
Medicines Co.
On Friday, shares in Parsippany, New
Jersey-based The Medicines Co. ended the session 1.64% lower
at $39.03. The stock recorded a
trading volume of 865,648 shares. The Company's shares have gained
15.00% on an YTD basis. The stock is trading below its 200-day
moving average by 6.47%. Moreover, shares of Medicines Co., which
provides medicines for patients in acute and intensive care
hospitals worldwide, have an RSI of 30.65. A free report on MDCO is
just a click away at:
http://dailystocktracker.com/registration/?symbol=MDCO
Supernus Pharma
Rockville, Maryland-based
Supernus Pharmaceuticals Inc.'s stock dropped 5.36%, to close the
day at $38.85. A total volume of
797,108 shares was traded, which was above their three months
average volume of 600,830 shares. The Company's shares have surged
21.79% in the last one month, 47.44% over the previous three
months, and 53.86% since the start of this year. The stock is
trading 15.92% and 46.29% above its 50-day and 200-day moving
averages, respectively. Additionally, shares of Supernus Pharma,
which focuses on the development and commercialization of products
for the treatment of central nervous system diseases in the US,
have an RSI of 62.79.
On June 01st, 2017,
research firm Piper Jaffray upgraded the Company's stock rating
from 'Neutral' to 'Overweight'. Sign up for your complimentary
research report on SUPN at:
http://dailystocktracker.com/registration/?symbol=SUPN
Pacira Pharma
Shares in Parsippany, New
Jersey headquartered Pacira Pharmaceuticals Inc. recorded a
trading volume of 621,454 shares. The stock ended at $44.20, slightly down 0.67% from the last trading
session. The Company's shares have gained 36.84% on an YTD basis.
The stock is trading above its 200-day moving average by 9.49%.
Furthermore, shares of Pacira Pharma, which develops, manufactures,
and commercializes proprietary pharmaceutical products primarily
for use in hospitals and ambulatory surgery centers in the US, have
an RSI of 39.64.
On May 23rd, 2017,
Pacira Pharma announced that James
Scibetta is resigning as the Company's President to become
CEO of an undisclosed, private early-stage oncology company. The
Company will allocate Mr. Scibetta's operational oversight
responsibilities to the current leadership team, and does not
intend to name a successor. Mr. Scibetta will remain with the
Company through June 30th,
2017, to ensure a seamless, transition period. Register for free on
DailyStockTracker.com and download the latest research report on
PCRX at:
http://dailystocktracker.com/registration/?symbol=PCRX
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA